1000 resultados para Dl-pyroangolensolide


Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [1:5 000], échelle d'1 pour 5000

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:2 500 000], échelle de 20 myriamètres [= 8 cm]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:1 100 000], échelle de 20 lieues de poste [= 7,8 cm]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:176 400], échelle de 6000 mètres [= 3,4 cm]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:2 128 000], échelle 10 myriamètres [= 4,7 cm]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:4 422 000]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:5 600], 100 mètres environ 200 pas [= 1,8 cm]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Échelle(s) : [ca 1:31 000]

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Avaliar os fatores de risco cardiovascular, com ênfase na hipertensão, e estratificá-los de acordo com o Escore de Risco de Framingham (ERF). Estudo com 154 profissionais que atuavam em aten-dimento pré-hospitalar na cidade de São Paulo e rodovia Br-116. Foi considerado significante o valor de p<0,05. A prevalência de hipertensão foi de 33%, sendo que 20,1% eram tabagistas, 47% ingeriam bebidas alcoólicas, 64% eram sedentários, 66% apresentaram obesidade/sobrepeso e 70% cintura abdominal alterada, glicemia>110mg/dL- 11%, colesterol total>200mg/dL- 36%, LDL-c>130mg/dL- 33%, HDL-c<60mg/dL- 89%, triglicérides>150mg/dL- 30% e proteína C reativa>0,5mg/dL- 16%. O ERF foi médio em 10,3% e alto em 1,3%. Na análise de regressão logística verificou-se que a hipertensão associou-se com as variáveis: HDL-c (odds ratio: 0,257) e ERF (odds ratio: 23,159). Houve forte associação entre ERF e hipertensão. Os dados chamam a atenção, por se tratar principalmente de profissionais da área da saúde relativamente jovens.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Analizamos un total de 669 biopsias hepáticas (557 percutáneas y 92 transyugulares) realizadas en 286 pacientes receptores de trasplante hepático con la intención de identificar factores de riesgo para el desarrollo de complicaciones infecciosas en relación a la biopsia hepática. Identificamos un total de 25 complicaciones en 24 pacientes (incidencia global de 3,7%). De ellas, 14 correspondieron a complicaciones infecciosas (2,09%). El principal factor de riesgo en nuestra serie fue el hecho de que los pacientes se encontrasen hospitalizados en el momento del procedimiento, reflejo de la mayor gravedad de esta población. Dentro de la población nosocomial, obtuvimos diferencias estadísticamente significativas en relación a los niveles de albúmina, con un riesgo estimado 3,7 veces mayor de desarrollar una infección en aquellos pacientes con niveles inferiores a 2,4 mg/dL.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Astrocytes are responsible for the majority of the clearance of extracellular glutamate released during neuronal activity. dl-threo-beta-benzyloxyaspartate (TBOA) is extensively used as inhibitor of glutamate transport activity, but suffers from relatively low affinity for the transporter. Here, we characterized the effects of (2S, 3S)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA), a recently developed inhibitor of the glutamate transporter on mouse cortical astrocytes in primary culture. The glial Na(+)-glutamate transport system is very efficient and its activation by glutamate causes rapid intracellular Na(+) concentration (Na(+)(i)) changes that enable real time monitoring of transporter activity. Na(+)(i) was monitored by fluorescence microscopy in single astrocytes using the fluorescent Na(+)-sensitive probe sodium-binding benzofuran isophtalate. When applied alone, TFB-TBOA, at a concentration of 1 muM, caused small alterations of Na(+)(i). TFB-TBOA inhibited the Na(+)(i) response evoked by 200 muM glutamate in a concentration-dependent manner with IC(50) value of 43+/-9 nM, as measured on the amplitude of the Na(+)(i) response. The maximum inhibition of glutamate-evoked Na(+)(i) increase by TFB-TBOA was >80%, but was only partly reversible. The residual response persisted in the presence of the AMPA/kainate receptor antagonist CNQX. TFB-TBOA also efficiently inhibited Na(+)(i) elevations caused by the application of d-aspartate, a transporter substrate that does not activate non-NMDA ionotropic receptors. TFB-TBOA was found not to influence the membrane properties of cultured cortical neurons recorded in whole-cell patch clamp. Thus, TFB-TBOA, with its high potency and its apparent lack of neuronal effects, appears to be one of the most useful pharmacological tools available so far for studying glial glutamate transporters.